# Reflection Agent Outputs

## reflection_1
**Reflection Agent Review: Cycle 2 Candidate‑Axis Validation Hypotheses**  
*(review mode: mechanistic plausibility, MK specificity, hypoxia specificity)*  

Below, each submitted hypothesis is evaluated against the evidence base, with particular attention to mandatory Seurat data (self‑reported by generation agents, not independently retrieved), MK‑sorted metabolomics, whole‑lung metabolomics gap, and the requirement to keep downstream axes provisional.

---

### **Hypothesis ID: Axis1_AMD1_immune (generation_metabolic)**
**Review decision: Promising but incomplete**

**Directional assessment:**  
- *Strengths:* Tightly anchored to MK methionine elevation and Amd1 upregulation; correctly labels downstream immune axis as provisional; identifies plausible polyamine immunomodulation.  
- *Weaknesses:* No direct evidence that MK‑derived polyamines reach perivascular immune cells at functional concentrations; whole‑lung polyamine levels not measured; immune phenotype is broadly defined.  
- *Reasoning quality:* Good; logic from metabolic shift to immune tone is coherent, and the key uncertainty (polyamine bioavailability) is acknowledged.  
- *Appropriate resolution:* Axis is appropriately broad; does not over‑resolve to specific T‑cell subsets.

**Evidence assessment:**  
- *User‑provided data:* Direct – methionine ↑ in PH MKs (metabolomics), Amd1 MK‑enriched and PH‑up (scRNA‑seq).  
- *Public data:* Not yet available; GSE289322 enrichment for arginine/proline metabolism would strengthen tissue‑level support but results are pending.  
- *Literature:* Inferred – polyamines can modulate immunity; no direct PH‑MK‑polyamine studies.  
- *Inference:* Polyamine effect on perivascular immune cells is plausible but not demonstrated.  
- *Speculation:* None beyond the provisional axis.

**Major concerns:** MK‑origin gap – diffusion of polyamines from MK to immune niches not proven; polyamine concentrations unknown; risk that MK‑intrinsic effect is not paracrine.

**Downstream‑axis assessment:**  
- *Broad axis:* Immune‑mediated.  
- *Candidate examples:* Spermidine influencing Th17‑like tone or macrophage polarization – all appropriately labeled provisional.  
- *What remains unresolved:* Which immune cells, which receptors, whether direct or EV‑mediated.  
- *MK‑origin gap:* As above.  
- *Falsification:* Conditional Amd1 KO should reduce perivascular immune activation; if immune readouts unchanged but remodeling still reduced, the axis is unlikely dominant. Good falsification criterion.

**Required revisions:** Include explicit note that whole‑lung polyamine measurements are missing and that immune modulation may be secondary.

**Experimental critique:**  
- *Strong points:* Conditional KO realistic, immune phenotyping feasible.  
- *Weak points:* No control for polyamine effects independent of immune modulation; polyamine measurement by mass spectrometry imaging would be needed.  
- *Missing controls:* Anti‑inflammatory blockade to distinguish immune‑mediated vs direct vascular effects.  
- *Falsification criteria:* Already provided.

**Final recommendation:** **Revise** – strengthen by specifying alternative direct routes and addressing polyamine bioavailability gap. Consider merging with other immune‑focused AMD1 hypotheses.

---

### **Hypothesis ID: Axis2_AMD1_vascular (generation_metabolic)**
**Review decision: Promising but incomplete**

**Directional assessment:**  
- *Strengths:* Direct connection of AMD1‑polyamine to PASMC mitogenesis; testable via PASMC proliferation readouts.  
- *Weaknesses:* No spatial evidence for MK‑PASMC proximity; polyamine diffusion and mitogenic threshold unclear; whole‑lung spermidine/spermine not measured.  
- *Reasoning quality:* Reasonable; correctly notes uncertainty about polyamine bioavailability.  
- *Appropriate resolution:* Does not over‑resolve receptor or signalling cascade; keeps axis broad.

**Evidence assessment:**  
- *User‑provided data:* Direct for Amd1/MK; indirect for PASMC mitogenic effect (inference from smooth muscle biology).  
- *Public data:* GSE289322 results pending; if whole‑lung polyamine pathway genes are upregulated, it would support.  
- *Literature:* Inferred – polyamines are known smooth muscle mitogens, but no MK‑PH studies.  
- *Inference:* MK‑derived polyamines acting as paracrine growth factors for PASMCs is plausible.  
- *Speculation:* Minimal.

**Major concerns:** Same MK‑origin gap; no evidence that MKs release polyamines directly into the media; PASMC proliferation could be driven by other MK products.

**Downstream‑axis assessment:**  
- *Broad axis:* Direct vascular‑wall.  
- *Candidate examples:* Spermidine activating mTOR or NMDA receptors – appropriately provisional.  
- *MK‑origin gap:* Proximity and polyamine secretion not shown.

**Required revisions:** Add immunostaining for MK location relative to media; propose co‑culture experiments with MKs and PASMCs to test mitogenicity.

**Experimental critique:**  
- *Strong points:* EdU/Ki67 readout straightforward; conditional KO.  
- *Weak points:* Difficulty attributing reduced proliferation solely to polyamines; other MK secretome factors may confuse.  
- *Missing

## reflection_2
# Reflection Agent Output

Cycle ID: 2

The following review critiques the hypotheses generated by multiple agents. The evaluation is based on the evidence summaries provided by the Tool Use Agent and Public Dataset Agent, the mandatory Seurat queries as reported by generation agents (but not independently verified), and user-provided metabolomics data. Critical gaps are highlighted, especially the lack of direct access to GSE289322 differential expression and GSEA results, which limits tissue-level validation. All downstream axes are assessed for appropriate provisional labeling.

---

## Hypothesis ID: Axis1_AMD1_immune (metabolic agent)
**Review decision:** Promising but incomplete  
**Directional assessment:**  
- **Strengths:** Anchored to the strongest shortlist chain (methionine ↔ Amd1). Amd1 is strongly MK-enriched and PH-up (log2FC 1.77, p=6.6e‑6). The metabolite elevation in MKs (methionine) is direct user data. The candidate downstream axis (immune-mediated) is plausible given known immunomodulatory effects of polyamines. The hypothesis avoids over‑resolving into a specific immune subset.  
- **Weaknesses:** The actual polyamines (spermidine/spermine) were not measured in MK metabolomics, so the link from Amd1 to polyamine production is inferred. The “immune‑mediated” axis is broadly defined; without spatial or receptor evidence, it remains highly speculative.  
- **Reasoning quality:** Good directional logic from data anchor to immune modulation to remodeling, but the chain has no experimental evidence that MK polyamines act on perivascular immune cells.  
- **Appropriate resolution:** Correctly broad; does not overcommit to Th17 or Treg.

**Evidence assessment:**  
- **User-provided data:** Direct for methionine MK elevation and Amd1 expression/PH shift.  
- **Public data:** GSE289322 GSEA for arginine/proline metabolism (polyamine context) would strengthen tissue-level relevance but not provided.  
- **Literature:** Supportive only in related fields (polyamines and immune function); no PH-specific data.  
- **Inference:** Polyamines modulate immune cell phenotypes – plausible but not proven in this context.  
- **Speculation:** That MK-derived polyamines reach effective concentrations in the perivascular niche and cause immune-mediated vascular remodeling.

**Major concerns:**  
- Absence of MK spermidine/spermine measurements.
- No direct evidence that MK polyamines traffic to target immune cells.
- Tissue-level pathway enrichment data missing.

**Downstream-axis assessment:**  
- **Broad axis:** Immune-mediated.
- **Candidate examples:** Provisional Th17-like polarization, macrophage reprogramming.
- **What remains unresolved:** Immune cell subset, receptor mechanism, effective polyamine concentration in tissue.
- **MK-origin gap:** Distance from MK to perivascular immune cells.
- **Direction-specific falsification:** If conditional Amd1 KO reduces polyamines but does not alter perivascular immune profiles, the immune axis is unlikely. Well stated.

**Required revisions:**  
- Must incorporate future measurement of spermidine/spermine in MKs or lung interstitium.  
- Would benefit from tissue-level GSEA results if available.  
- Provide a more specific experimental readout for immune modulation (e.g., cytokine panel, flow cytometry for Th17/Treg) rather than generic “immune cell composition”.

**Experimental critique:**  
- **Strong points:** MK‑specific knockout (Pf4‑Cre) is feasible; endpoint muscularization measurement standard.  
- **Weak points:** Immune readouts are not precisely defined; risk of missing subtle phenotypic shifts.  
- **Missing controls:** Should include MK-depletion control to show dependence on MKs, and possibly a polyamine rescue experiment.  
- **Falsification criteria:** Adequate.

**Final recommendation to PI:** Revise (incorporate polyamine measurements, precise immune profiling, and tissue-level validation if possible).

---

## Hypothesis ID: Axis2_AMD1_vascular (metabolic agent)
**Review decision:** Promising but incomplete  
**Directional assessment:**  
- **Strengths:** Same solid data anchor. Direct vascular-wall action of polyamines is plausible given their known mitogenic effects on smooth muscle. Hypothesis is simple and testable.  
- **Weaknesses:** No direct data that MKs are positioned near PASMCs or that polyamine concentrations reach mitogenic levels in the perivascular space. Polyamine receptor(s) on PASMCs not specified.  
- **Reasoning quality:** Logical chain from AMD1 to polyamine release to PASMC proliferation, but the bridging evidence is weak.  
- **Appropriate resolution:** Keeps axis broad, does not over-resolve receptor.

**Evidence assessment:**  
- **User-provided data:** Direct for Amd1/MK.  
- **Public data:** Unavailable for tissue-level polyamine/purine signature.  
- **Literature:** Indirect – polyamines as smooth muscle mitogens in systemic vessels.  
- **Inference:** MK-derived polyamines could act paracrine mitogens.  
- **Speculation:** That this is the dominant remodeling mechanism.

**Major concerns:**  
- Bioavailability and spatial proximity are unproven.  
- Might be confounded by other MK products (PDGF, TGF-beta) if Amd1 KO affects them.  
- No measurement of polyamine gradient or PASMC polyamine uptake.

**Downstream-axis assessment:**  
- **Broad axis:** Direct vascular-wall.  
- **Candidate examples:** eIF5A hypusination, mTOR/S6K activation.  
- **What remains unresolved:** Polyamine transporter on PASMCs, mitogenic threshold.  
- **MK-origin gap:** Spatial relationship.  
- **Falsification:** Good – if Amd1 KO reduces polyamines but not PASMC proliferation, the axis fails.

**Required revisions:**  
- Add spatial validation (immunofluorescence for MK proximity to media).  
- Propose in vitro demonstration that hypoxic MK conditioned medium stimulates PASMC proliferation in a spermidine-dependent manner.

**Experimental critique:**  
- **Strong points:** Simple muscularization readouts.  
- **Weak points:** Proliferation measured only in vivo, could be confounded by systemic effects.  
- **Missing controls:** Isolated PASMC response to polyamines without MKs; polyamine inhibitor rescue.  
- **Falsification criteria:** Acceptable.

**Final recommendation to PI:** Revise (add spatial and in vitro evidence; incorporate polyamine inhibition controls).

---

## Hypothesis ID: Axis3_AMD1_EV (metabolic agent)
**Review decision:** Weak (pending mandatory EV gene expression confirmation)  
**Directional assessment:**  
- **Strengths:** Exploits MK EV secretion capability; if EV biogenesis genes (Rab27a, Tsg101) are MK-enriched and hypoxia-up, the premise is strengthened.  
- **Weaknesses:** The mandatory Seurat query for these genes was not independently verified; only reported by agents. The hypothesis is heavily reliant on speculative EV loading of polyamines, which is not directly supported. No metabolomics data on EV polyamine content.  
- **Reasoning quality:** Logical but built on multiple unverified assumptions (EV machinery expression, polyamine loading, fibroblast recipient).  
- **Appropriate resolution:** Provisional, but the EV axis is not yet justified by the current evidence.

**Evidence assessment:**  
- **User-provided data:** Amd1, but no data on EV-related gene expression (only agent self-report).  
- **Public data:** None.  
- **Literature:** Only general EV biology, no MK‑EV‑polyamine‑fibroblast axis.  
- **Inference:** Polyamines can be encapsulated in EVs, but no direct proof.  
- **Speculation:** That MK EVs target fibroblasts and drive ECM remodeling.

**Major concerns:**  
- Missing mandatory expression data for Rab27a, Tsg101, and Lox family – cannot evaluate feasibility.  
- No evidence polyamines are EV-selective in MKs.  
- The stromal remodeling readout (Lox, collagen) is not linked to AMD1‑polyamine.

**Downstream-axis assessment:**  
- **Broad axis:** EV/stromal.  
- **Candidate examples:** Fibroblast activation via EV-spermidine.  
- **What remains unresolved:** EV content, fibroblast specificity.  
- **MK-origin gap:** Need to confirm that MK-derived EVs contain polyamines.  
- **Falsification:** Conditioned on EV machinery expression.

**Required revisions:**  
- Obtain verified expression results for Rab27a, Tsg101; if negative, discard hypothesis.  
- Propose direct measurement of EV polyamine content from MK supernatant.

**Experimental critique:**  
The hypothesis is premature; even if the EV genes are expressed, the test requires EV isolation and functional assays, which are technically demanding and lack direct polyamine link.

**Final recommendation to PI:** Deprioritize until mandatory EV gene data confirmed and polyamine EV-loading shown.

---

## Hypothesis ID: Axis4_Inosine_immune (metabolic agent)
**Review decision:** Strong  
**Directional assessment:**  
- **Strengths:** Direct compound-enzyme link (inosine→Pnp) and strong MK PH-up regulation (Pnp log2FC 1.74, p=3.8e‑6). The immune-modulatory role of adenosine/inosine is well established, and the hypothesis bridges MK purine metabolism to perivascular immunosuppression. Does not over-resolve receptor subtype.  
- **Weaknesses:** Inosine must be converted to adenosine (requires ecto‑enzymes) to activate adenosine receptors; this step not demonstrated in MK niche. Whole-lung adenosine levels unknown.  
- **Reasoning quality:** Explains how MK purine catabolism could shape immune environment, but key conversion gap remains.  
- **Appropriate resolution:** Broad immune-mediated axis, correctly provisional.

**Evidence assessment:**  
- **User-provided data:** Direct – inosine up in MKs, Pnp up in MKs.  
- **Public data:** GSE289322 purine metabolism pathway enrichment would support but unavailable.  
- **Literature:** Adenosine‑induced immunosuppression in tumors and lung disease; no MK-specific data.  
- **Inference:** MK-derived inosine/adenosine could suppress effector immunity.  
- **Speculation:** That this immune suppression is pro‑remodeling (rather than protective).

**Major concerns:**  
- CD73 expression on MKs or neighboring cells unknown; in vivo adenosine generation not measured.  
- The net effect of adenosine in PH remains debated (A2B can promote remodeling, but also vasodilate). The hypothesis assumes a dominant pro‑remodeling effect.

**Downstream-axis assessment:**  
- **Broad axis:** Immune-mediated suppression.  
- **Candidate examples:** Adenosine A2B on macrophages, A2A on T cells.  
- **What remains unresolved:** Which nucleoside, which receptor, which immune cell.  
- **MK-origin gap:** Contribution of MK-derived inosine vs other sources.  
- **Falsification:** Conditional Pnp KO should reduce adenosine and alter immune phenotypes; if immune profile unchanged, axis unlikely. Good.

**Required revisions:**  
- Clarify CD73 expression on MKs or perivascular cells.  
- Include adenosine concentration measurements in lung or BALF.  
- Consider rescue with adenosine receptor agonists/antagonists.

**Experimental critique:**  
- **Strong points:** Feasible Pnp KO; immune readouts testable.  
- **Weak points:** Need to distinguish inosine vs adenosine effects; receptor‑blocking experiments may be ambiguous.  
- **Missing controls:** MK‑specific CD73 KO if expression confirmed.  
- **Falsification criteria:** Adequate.

**Final recommendation to PI:** Advance with additional validation (CD73 expression, inosine/adenosine tissue levels).

---

## Hypothesis ID: Axis5_Inosine_vascular (metabolic agent)
**Review decision:** Promising but incomplete  
**Directional assessment:**  
- **Strengths:** Builds on same solid inosine/Pnp anchor. Salvage pathway in dividing cells is a plausible concept. Could be a novel metabolic support mechanism.  
- **Weaknesses:** Proliferation of PASMCs is usually driven by growth factor/receptor signals, not insufficient purine precursors. Inosine salvage may be redundant. No evidence that MK-derived inosine is quantitatively important. No data on nucleoside transporter expression in PASMCs.  
- **Reasoning quality:** Interesting but less compelling than immune axis; the hypothesis stretches the metabolic logic.  
- **Appropriate resolution:** Broad direct vascular-wall axis; appropriate.

**Evidence assessment:**  
- **User-provided data:** Inosine/Pnp as above.  
- **Public data:** None.  
- **Literature:** General concept of nucleoside salvage in cancer, but not in MK‑PASMC crosstalk.  
- **Inference:** Inosine as a metabolic fuel for PASMC proliferation.  
- **Speculation:** That inosine is rate-limiting for proliferation.

**Major concerns:**  
- In vivo purine salvage is unlikely to be limiting because cells can synthesize purines de novo; hypoxia may impair de novo synthesis, but that's not addressed.  
- Inosine uptake and incorporation data missing.

**Downstream-axis assessment:**  
- **Broad axis:** Direct vascular-wall.  
- **Candidate examples:** Nucleoside transporter ENT1/2, ATP/DNA synthesis.  
- **What remains unresolved:** Rate-limiting step, redundancies.  
- **MK-origin gap:** Quantitative contribution of MK inosine vs local cellular purines.  
- **Falsification:** Conditional Pnp KO and inosine rescue – a reasonable test, but if inosine does not rescue, still doesn't disprove; may reflect conversion to adenosine.

**Required revisions:**  
- Provide direct evidence of inosine uptake and nucleotide labeling in PASMCs via MK co-culture.  
- Compare to adenosine receptor-dependent proliferation.

**Experimental critique:**  
- **Strong points:** Tracer-based LC‑MS approach is specific.  
- **Weak points:** Technically complex; isotope tracing in PH model is challenging.  
- **Missing controls:** Adenosine receptor blockade to separate salvage from signaling.  
- **Falsification criteria:** Somewhat over‑interpreted; failure to rescue by exogenous inosine does not exclude that endogenous inosine was already sufficient.

**Final recommendation to PI:** Revise – reduce priority relative to immune axis; but could be kept as a secondary hypothesis.

---

## Hypothesis ID: Axis6_Matricellular_exploratory (metabolic agent)
**Review decision:** Reject for now – no data to evaluate.  
**Directional assessment:** The hypothesis is explicitly conditioned on unperformed Seurat queries. It is a placeholder, not a testable hypothesis with current evidence.  
**Evidence assessment:** ZERO. The mandatory Seurat results

## reflection_3
**Reflection Agent Review – Cycle 2 Hypotheses**  
*Review mode: experimental design, falsifiability, controls, feasibility.*  
*All hypotheses are assessed against the mandatory Seurat/Public‑data analyses as summarized in the cycle evidence base.*

---

### Hypothesis ID: Axis1_AMD1_immune (from generation_metabolic)

**Review decision:** Promising but incomplete

**Directional assessment:**  
- **Strengths:** Direct metabolite (methionine) + enzyme (Amd1) anchor; MK‑enriched and PH‑up; immune‑mediated axis is plausible because polyamines are known immunomodulators.  
- **Weaknesses:** The polyamine‑immune link in the hypoxia‑PH lung remains speculative; no whole‑lung polyamine measurement; no MK‑to‑immune‑cell spatial evidence.  
- **Reasoning quality:** Good – connects methionine‑AMD1 to polyamine production and proposes a broad immune‑mediated route, explicitly labelling candidate examples (Th17) as provisional.  
- **Appropriate resolution:** Correctly stays at directional level without over‑resolving immune subsets.

**Evidence assessment:**  

| Source | Level | Details |
|--------|-------|---------|
| User‑provided scRNA‑seq | Direct | *Amd1* MK enriched, PH‑up (log2FC 1.77) |
| User‑provided metabolomics | Direct | Methionine up in PH‑MKs (log2FC 3.26) |
| Public data (GSE289322) | Not available | DE/GSEA results missing; cannot assess tissue‑level corroboration |
| Literature | Inferred | Polyamines influence T‑cell/macrophage function in other contexts; no direct PH‑MK studies |
| Biological inference | Speculative | MK‑derived polyamines reach perivascular immune cells at functional concentrations |

**Major concerns:**  
- Polyamines (spermidine/spermine) were not measured in MKs or whole lung – chain is inferred only from methionine and *Amd1* expression.  
- No demonstration that Amd1 knockout reduces polyamines in MKs under hypoxia.  
- The immunosuppressive/pro‑remodeling net effect of polyamines in the lung is unproven.

**Downstream‑axis assessment:**  
- **Broad axis:** Immune‑mediated (polyamines → T‑cell/Th17‑like skew, macrophage modulation).  
- **Candidate examples:** Spermidine‑suppressed Treg, enhanced IL‑17 (provisional).  
- **What remains unresolved:** Immune cell target(s), spatial range of MK‑derived polyamines, required concentration.  
- **MK‑origin gap:** Not addressed – MK proximity to immune niches not shown.  
- **Falsification criterion:** Adequate – *Amd1*‑KO should reduce perivascular immune activation and muscularization; if immune changes absent despite reduced polyamines, axis disproven.

**Required revisions:**  
- Explicitly acknowledge absence of polyamine measurement and propose direct polyamine quantification in MKs/lung tissue.  
- Add control: *Amd1*‑KO rescue with exogenous spermidine to confirm polyamine‑specific effect.

**Experimental critique:**  
- **Strong points:** Conditional *Amd1*‑KO (Pf4‑Cre) is well‑suited; flow‑based immune profiling coupled with muscularization is feasible.  
- **Weak points:** No direct readout of polyamine concentrations in perivascular niche; immune readouts are broad.  
- **Missing controls:** Littermate WT controls; Amd1‑flox without Cre; pharmacological polyamine blocking (DFMO) as complementary approach; polyamine replacement to test specificity.  
- **Falsification criteria:** Well defined: if MK‑specific Amd1 deletion fails to alter immune composition or muscularization, the immune axis is unsupported.

**Final recommendation:** **Revise** – include direct polyamine quantification, and add orthogonal falsification with polyamine synthesis inhibitors (e.g., DFMO) to confirm a polyamine‑dependent step.

---

### Hypothesis ID: Axis2_AMD1_vascular (from generation_metabolic)

**Review decision:** Promising but incomplete

**Directional assessment:**  
- **Strengths:** Polyamines are known smooth muscle cell mitogens; MK‑enriched AMD1 with methionine accumulation supports a paracrine mitogen role.  
- **Weaknesses:** No evidence of polyamine concentrations in the vessel wall; MK spatial proximity to PASMCs not established; receptor‑level mechanism undefined.  
- **Reasoning quality:** Acceptable – suggests direct mitogenic action on PASMCs, with eIF5A hypusination as a candidate example.  
- **Appropriate resolution:** Keeps direct vascular‑wall axis broad, does not over‑specify receptor.

**Evidence assessment:**  

| Source | Level | Details |
|--------|-------|---------|
| User scRNA‑seq + metabolomics | Direct | Amd1/methionine data |
| Public data | Missing | GSE289322 DE for proliferation signatures not available |
| Literature | Inferred | Polyamines can promote PASMC growth in systemic vessels; no PH‑MK evidence |
| Inference | Speculative | MK‑derived polyamines reach PASMCs at mitogenic levels |

**Major concerns:**  
- No MK‑to‑PASMC proximity data; lung MKs may be interstitial not directly adjacent to media.  
- Polyamine export mechanism unknown – are they secreted, released via EVs, or from cell lysis?  
- eIF5A hypusination is a candidate example; no data linking AMD1 to eIF5A hypusination in MKs.

**Downstream‑axis assessment:**  
- **Broad axis:** Direct vascular‑wall (polyamines → PASMC proliferation).  
- **Candidate examples:** Spermidine activating NMDA receptors or eIF5A hypusination (provisional).  
- **Unresolved:** MK proximity, polyamine transport, contribution relative to oxygen‑dependent PASMC responses.  
- **MK‑origin gap:** Not addressed.  
- **Falsification criterion:** Acceptable: if *Amd1*‑KO reduces polyamines but not PASMC proliferation, axis disproven.

**Required revisions:**  
- Include immunohistochemistry or spatial transcriptomics to show MK–PASMC co‑localization.  
- Measure spermidine/spermine in microdissected vessel wall.

**Experimental critique:**  
- **Strong points:** *Amd1*‑KO plus EdU/Ki67 readout in media is direct.  
- **Weak points:** Cannot distinguish direct mitogenic effect from secondary signals (e.g., hypoxia itself inducing proliferation); need polyamine‑specific blocker (e.g., DFMO) in addition to KO.  
- **Missing controls:** Pharmacological inhibition of polyamine synthesis in WT mice to mimic KO; rescue with spermidine infusion.  
- **Falsification criteria:** Sensible but will be confounded if MKs release other mitogens unaffected by Amd1 deletion.

**Final recommendation:** **Revise** – add spatial validation and a polyamine synthesis inhibitor arm to confirm pathway specificity.

---

### Hypothesis ID: Axis3_AMD1_EV (from generation_metabolic)

**Review decision:** Weak (conditional on mandatory Seurat results not yet verified)

**Directional assessment:**  
- **Strengths:** MKs are prolific EV producers; polyamines are small and could be packaged.  
- **Weaknesses:** EV biogenesis genes (*Rab27a*, *Tsg101*) expression in MKs is only self‑reported, not directly verified; polyamine loading into EVs not demonstrated; fibroblast activation endpoint is speculative.  
- **Reasoning quality:** Speculative chain – relies on EV machinery present and polyamine‑loading, which are untested.  
- **Appropriate resolution:** Acceptable if mandatory gene results are positive; currently unresolved.

**Evidence assessment:**  

| Source | Level | Details |
|--------|-------|---------|
| User scRNA‑seq (self‑reported) | Indirect | Rab27a enrichment reported, but not verified; Tsg101 modest increase |
| User metabolomics | Direct | Methionine, but no polyamine‑EV data |
| Public data | Missing | None |
| Literature | Inferred | EV metabolite loading is possible; no MK‑polyamine‑EV‑fibroblast studies |
| Inference | Speculative | Polyamines are loaded into MK‑EVs and delivered to fibroblasts |

**Major concerns:**  
- Entire axis depends on unconfirmed EV gene expression; if Rab27a/Tsg101 are not genuinely MK‑enriched or hypoxia‑responsive, the hypothesis collapses
